Dai et al. conducted a study where they used autologous bispecific CAR-Ts targeting both CD19 and CD22 on a group of six adult patients with recurrent B-cell acute lymphoblastic leukemia. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.